WORCESTER, Mass.–(BUSINESS WIRE)–RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, Inc., positive data were generated demonstrating that RXi’s sd-rxRNA™ technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.
The parties have successfully applied RXi’s proprietary sd-rxRNA (self-delivering rxRNA) technology to create microRNA mimics, or artificial copies of microRNAs. In particular, they have demonstrated efficacy in down-regulating a reporter gene whose expression is controlled by the microRNA in cell culture model systems developed by miRagen. Increasing the level of particular microRNAs by using therapeutic mimics may treat certain diseases, including cardiovascular, cancer, inflammatory, fibrotic and metabolic disorders. This data will be presented in a poster at the upcoming Keystone Symposia’s MicroRNAs and Non-Coding RNAs and Cancer meeting February 11-16, 2011 and will be available on RXi’s website after the conference www.rxipharma.com.
(read the entire release… )
Incoming search terms for this article:
by Chris on November 12, 2009
in News
11/12/09 – CAMBRIDGE, Mass.–( Business Wire)–Alnylam Pharmaceuticals, Inc. an RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET
Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. In addition, Alnylam will host two guest speakers:
- Professor Allan R. Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus (RSV) infection in the lung transplant patient population; and,
- Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School Royal Free Hospital, will discuss transthyretin (TTR)-mediated amyloidosis.
10/28/09 – CARLSBAD, Calif. & CAMBRIDGE, Mass.–(Business Wire)– Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc. , announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the `Esau` patent family (US Application Serial No. 10/909,125). The Esau patent estate, which is owned exclusively by Regulus, represents one of the earliest filings in the microRNA intellectual property landscape, and is fundamental to the discovery, development, and commercialization of microRNA therapeutics.
“Regulus is advancing a new class of innovative medicines based on microRNAs. Indeed, microRNA therapeutics represent a new frontier of pharmaceutical research where an entire pathway of human disease can be targeted,” said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics. “This Notice of Allowance is the first in the Esau series, and we expect many more patents covering microRNA therapeutics to issue from this important and early patent family.”
Loading ...
